Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8:34:e20240732.
doi: 10.1590/S2237-96222025v34e20240732.en. eCollection 2025.

Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019

[Article in English, Portuguese]
Luis Phillipe Nagem Lopes  1   2 , Augusto César Sousa Raimundo  3 , Alexander Itria  4 , Rosângela Caetano  2 , Luciane Cruz Lopes  1
Affiliations

Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019

[Article in English, Portuguese]
Luis Phillipe Nagem Lopes et al. Epidemiol Serv Saude. .

Abstract
in English, Spanish

Objective: To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).

Methods: This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts ​​recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).

Results: The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).

Conclusion: The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.

Objetivo: Analizar el impacto presupuestario del uso de risperidona para el trastorno del espectro autista (TEA) en el Sistema Único de Salud (SUS).

Métodos: Se trata de un estudio de caso con enfoque documental, que comparó las estimaciones de los análisis de impacto presupuestario presentados en los informes de recomendaciones de la Comisión Nacional para la Incorporación de Tecnologías (Conitec) para el uso de risperidona en TEA con los valores recalculados a partir de los datos de demanda medida. El recálculo se realizó para niños (0-17 años) y adultos (≥18 años) utilizando datos de la plataforma Sala de Inteligencia en Salud Abierta sobre la dispensación de risperidona en el SUS, considerando un horizonte temporal de tres años (2017-2019).

Resultados: El impacto presupuestario total a lo largo de tres años para el uso de risperidona en TEA presentó diferencias entre la demanda medida (niños: R$ 10.389.702,70; adultos: R$ 15.075.767,80) y la estimada por Conitec en los informes de recomendaciones (niños: R$ 6.579.809,00; adultos: R$ 9.877.790,18).

Conclusión: El impacto presupuestario del uso de risperidona en TEA, basado en la demanda medida, fue diferente del impacto inicialmente previsto en los informes de recomendaciones de Conitec.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None to declare.

Similar articles

See all similar articles

References

    1. Witter S, Thomas S, Topp SM, Barasa E, Chopra M, Cobos D. Health system resilience: a critical review and reconceptualisation. Lancet Glob Health. 2023;11(9) - PubMed
    1. Silva SN, Mello NF, Ribeiro LR, Silva RE, Cota G. Implementação de tecnologias em saúde no Brasil: análise de orientações federais para o sistema público de saúde. Cienc Saude Colet. 2024;29 - PubMed
    1. Silva MT, Silva EN, Pereira MG. Análise de impacto orçamentário. Epidemiol Serv Saude. 2017;26(2) - PubMed
    1. Lopes LPN, Itria A, Lopes LC. Budget impact analysis of risperidone use and adverse event monitoring in autism spectrum disorder in Brazil: assessment of theoretical versus real data. Pharmacoecon Open. 2023;7(6) - PMC - PubMed
    1. Geenen JW, Boersma C, Klungel OH, Hövels AM. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ. 2019;20(6) - PMC - PubMed